What enzyme is deficient in Gaucher's disease?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 30, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Enzyme Deficient in Gaucher Disease

Gaucher disease is caused by a deficiency of the lysosomal enzyme acid β-glucocerebrosidase (also called glucocerebrosidase or β-glucosidase), which is encoded by the GBA gene. 1

Pathophysiology

  • Acid β-glucocerebrosidase normally catalyzes the hydrolysis of the sphingolipid glucocerebroside (glucosylceramide) into glucose and ceramide. 2, 3

  • The enzymatic deficiency causes accumulation of glucosylceramide (GL-1) primarily in the lysosomal compartment of macrophages, giving rise to foam cells or "Gaucher cells." 2

  • This accumulation occurs predominantly in the reticuloendothelial system, affecting the liver, spleen, bone marrow, and other organs. 2, 4

Diagnostic Confirmation

  • Diagnosis is confirmed by demonstrating deficient acid β-glucocerebrosidase enzymatic activity in leukocytes. 1, 5

  • If leukocyte GBA enzyme activity is low on repeat testing, proceed to GBA gene sequencing for molecular confirmation. 1

  • Identification of biallelic pathogenic variants in the GBA1 gene provides genetic confirmation and may offer prognostic information. 6, 5

Clinical Consequences of Enzyme Deficiency

  • Type 1 (non-neuronopathic): Hepatosplenomegaly, thrombocytopenia, anemia, and bone disease without primary neurological involvement. 1, 7

  • Type 2 (acute neuronopathic): Rapidly progressive with severe neurological manifestations, often fatal in early childhood. 6, 8

  • Type 3 (chronic neuronopathic): Variable neurological involvement including seizures, bulbar palsy, hypertonia, and supranuclear gaze palsy. 6, 8

Important Clinical Caveat

  • Carriers of GBA1 mutations have an increased risk of developing Parkinson's disease, which should be addressed during genetic counseling. 6, 5

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments.

International journal of molecular sciences, 2017

Guideline

Genetic Testing for Gaucher Disease

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Gaucher's disease: a review.

The Annals of pharmacotherapy, 1996

Research

Gaucher's disease in Lithuania: its diagnosis and treatment.

Medicina (Kaunas, Lithuania), 2011

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.